News | Artificial Intelligence | March 02, 2021

Philips Partners with DiA Imaging Analysis to Enhance Ultrasound

 

 

Philips and DiA Imaging Analysis Ltd., a leading provider of AI-powered applications for ultrasound, announced a strategic partnership to deliver automated solutions to clinicians at the point-of-care. Philips’ industry leading ultrasound image quality combined with DiA’s AI library of automated solutions will help increase diagnostic confidence, operational efficiency, and access to care for Point-of-Care customers in and out of the hospital.

March 2, 2021 —  Philips and DiA Imaging Analysis Ltd., a leading provider of AI-powered applications for ultrasound, announced a strategic partnership to deliver automated solutions to clinicians at the point-of-care. Philips’ industry leading ultrasound image quality combined with DiA’s AI library of automated solutions will help increase diagnostic confidence, operational efficiency, and access to care for Point-of-Care customers in and out of the hospital.

Philips continues to build suites of intelligent and automated enhancements integrated into Radiology workflows across its portfolio to benefit customers and patients alike. By facilitating the development and integration of AI-enabled applications, Philips aims to enhance its ability to deliver on the Quadruple Aim of better patient outcomes, improved patient and staff experiences and lower cost of care. The integration of AI applications within ultrasound technology can also help lead to improved access to care.

While ultrasound is a cost-efficient diagnostic imaging modality, it currently requires a significant level of operator experience and visual interpretation to use it effectively. In particular, the subjectivity and variability associated with visual interpretation pose a challenge for longitudinal assessments to gauge patient improvement or deterioration. To reduce the variability, improve the efficiency and increase the accuracy of image analysis, DiA Imaging has developed FDA cleared and CE-marked AI-enabled 2-D ultrasound applications.“This partnership with DiA Imaging Analysis reinforces Philips’ commitment to integrating AI partners into the Radiology workflow ecosystem, from the modality, to interpretation, all the way through to results communication,” said Kees Wesdorp, Chief Business Leader, Precision Diagnosis at Philips. “Through our strategic partnership with DiA Imaging Analysis, we can deliver unprecedented diagnostic confidence and operational efficiency to point-of-care ultrasound imaging, as well as widen access to high quality and timely care both inside and outside of hospitals.”   

“With superb image quality and ability to operate with smartphones and tablets, Philips Ultrasound devices are widely accepted as the industry’s most advanced solution for point-of-care imaging. As such, it is the ideal platform for deploying AI-enabled solutions that will benefit patients by helping clinicians to make better-informed decisions,” said Hila Goldman Aslan, CEO and Co-Founder, of DiA Imaging Analysis Ltd.

DiA’s AI technology automates the process of manually capturing and visually analyzing ultrasound images. The company’s LVivo Toolbox includes a range of FDA cleared and CE marked automated AI-enabled apps focused on cardiac and abdominal ultrasound analysis to help support clinicians with varying levels of ultrasound experience.

For more information: www.philips.com.sg/healthcare

Related Content

CDC and FDA Call for Pause on Janssen COVID-19 Vaccine Due to Rare Blood Clots #COVID19 #Janssen
Feature | Coronavirus (COVID-19) | April 15, 2021 | By Dave Fornell
April 15, 2021 — The U.S.
#SiemensHealthineers #Varian #Siemens The transformative combination accelerates the company’s impact on #global #healthcare and establishes a strong partner for #customers and #patients along the entire #cancer care continuum and for many of the most threatening #diseases
News | Radiology Business | April 15, 2021
April 15, 2021 — Siemens Healthineers AG an
A doctor reading #CXR scans using #SenseCare-Chest #DR Pro #diagnostic #software.

A doctor reading CXR scans using SenseCare-Chest DR Pro diagnostic software.

News | Artificial Intelligence | April 14, 2021
April 14, 2021 — SenseTime, a world-leading...
Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

Comparisons of high definition and standard definition infrared imaging for digital histopathology. Image courtesy of the Beckman Institute

News | Breast Imaging | April 14, 2021
April 14, 2021 — Detecting and analyzing breast cancer
The U.S. Food and Drug Administration (#FDA) authorized marketing of #Medtronic's #GIGenius, the first device that uses #artificialintelligence (#AI) based on #machinelearning to assist #clinicians in detecting #lesions (such as #polyps or suspected tumors) in the #colon in real time during a c#olonoscopy.

The GI Genius intelligent endoscopy module works in real-time, automatically identifying and marking (with a green box) abnormalities consistent with colorectal polyps, including small flat polyps.

News | Artificial Intelligence | April 12, 2021
A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | April 09, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine screenings, when compared with traditional mammography, according to a large study from Lund University in Sweden. The results are published in the journal Radiology.

Getty Images

News | Breast Imaging | April 09, 2021
April 9, 2021 — 3-D mammography reduces the number of breast cancer cases diagnosed in the period between routine scr
IV contrast-enhanced 2-mSv 4-mm-thick transverse and coronal (b) CT images show inflamed diverticula (arrows), segmental colonic wall thickening, and adjacent pericolic fat stranding. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

IV contrast-enhanced 2-mSv 4-mm-thick transverse and coronal (b) CT images show inflamed diverticula (arrows), segmental colonic wall thickening, and adjacent pericolic fat stranding. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Computed Tomography (CT) | April 09, 2021
April 9, 2021 — According to an open-acc...